ESR1 and neoplasm: We also did not observe higher expression of ERBB2 in ER − HER2 + compared to ER + HER2 + cell lines and tumours, which speaks against HER2 amplification level and/or expression driving the observed difference in EDI3 expression between these two subtypes.